3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pembrolizumab
30
Nivolumab
30
cabozantinib
20
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
belzutifan
13
lenvatinib
11
Axitinib
9
Specimen Handling
8
Sunitinib
7
durvalumab
5
CTLA-4 Antigen
5
tislelizumab
4
atezolizumab
4
Radiosurgery
4
Interleukin-2
4
Everolimus
4
Biopsy
4
Bevacizumab
4
pazopanib
3
avelumab
3
aldesleukin
3
Immunoglobulin G
3
Disulfides
3
palbociclib
2
fludarabine
2
entinostat
2
adavosertib
2
Surveys and Questionnaires
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Renal Cell
×
zimberelimab
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled